Lilly, B-Ingelheim deal adds to buzz in Indian diabetes market
This article was originally published in Scrip
Executive Summary
Global partners in the diabetes segment, Boehringer Ingelheim and Lilly, have entered into an India-specific co-promotion deal for a basket of diabetes compounds in both late-stage development or on the market, adding to the string of such alliances in the country.